Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue.

TitleEpstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue.
Publication TypeJournal Article
Year of Publication2002
AuthorsHeath JA, Broxson EH, Dole MG, Filippa DA, George D, Lyden D, Dunkel IJ
JournalJ Pediatr Hematol Oncol
Volume24
Issue2
Pagination160-3
Date Published2002 Feb
ISSN1077-4114
KeywordsAcyclovir, Antibodies, Monoclonal, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Antiviral Agents, Carboplatin, Central Nervous System Neoplasms, Child, Preschool, Combined Modality Therapy, Cyclophosphamide, Disease Progression, Epstein-Barr Virus Infections, Etoposide, Eye Enucleation, Eye Neoplasms, Fatal Outcome, Hematopoietic Stem Cell Transplantation, Herpesvirus 4, Human, Humans, Immunocompromised Host, Immunoglobulins, Intravenous, Immunosuppressive Agents, Immunotherapy, Lymphoma, Large B-Cell, Diffuse, Male, Meningeal Neoplasms, Methylprednisolone, Neoplasm Recurrence, Local, Neoplasms, Second Primary, Optic Nerve Neoplasms, Radiotherapy, Adjuvant, Retinoblastoma, Rituximab, Thiotepa, Vincristine
Abstract

Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) is a serious disorder seen in various states of immunodeficiency, often with a fatal outcome. In this article, a patient with EBV-lymphoma after autologous stem cell rescue for treatment of a nonhematologic solid tumor is described. The child, a 4-year-old boy, had unilateral retinoblastoma with metastatic spread to the central nervous system. He had previously received both local tumor bed and craniospinal radiation therapy together with intensive myeloablative alkylator chemotherapy before autologous stem cell rescue. Histologically confirmed lymphoma with evidence of active EBV proliferation developed within cervical lymph nodes 3 weeks after his first autologous stem cell rescue. A complete clinical remission of the lymphadenopathy was obtained after infusions of rituximab (an anti-CD20 monoclonal antibody), acyclovir, and high-titer anticytomegalovirus immunoglobulin. The patient died approximately 6 months later of persistent and progressive retinoblastoma without any clinical evidence of lymphoma. It is concluded that EBV-LPD should be included in the differential diagnosis in patients in whom lymphadenopathy develops after autologous stem cell rescue.

DOI10.1097/00043426-200202000-00022
Alternate JournalJ Pediatr Hematol Oncol
PubMed ID11998794